{"id":"https://openalex.org/W2083480184","doi":"https://doi.org/10.1002/ajh.21904","title":"Thalidomide versus bortezomib based regimens as first\u2010line therapy for patients with multiple myeloma: A systematic review","display_name":"Thalidomide versus bortezomib based regimens as first\u2010line therapy for patients with multiple myeloma: A systematic review","publication_year":2010,"publication_date":"2010-10-19","ids":{"openalex":"https://openalex.org/W2083480184","doi":"https://doi.org/10.1002/ajh.21904","mag":"2083480184","pmid":"https://pubmed.ncbi.nlm.nih.gov/21120867"},"language":"en","primary_location":{"id":"doi:10.1002/ajh.21904","doi":"https://doi.org/10.1002/ajh.21904","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.21904","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.21904","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.21904","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100440708","display_name":"Ambuj Kumar","orcid":"https://orcid.org/0000-0003-1260-6694","observed_orcids":["https://orcid.org/0000-0003-1260-6694"]},"institutions":[{"id":"https://openalex.org/I2613432","display_name":"University of South Florida","ror":"https://ror.org/032db5x82","country_code":"US","type":"education","lineage":["https://openalex.org/I2613432"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ambuj Kumar","raw_affiliation_strings":["Center for Evidence-based Medicine & Health Outcome Research, University of South Florida. akumar1@health.usf.edu","Center for Evidence-based Medicine & Health Outcome Research, University of South Florida","Department of Health Outcomes and Behavior, Moffitt Cancer Center & Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Evidence-based Medicine & Health Outcome Research, University of South Florida. akumar1@health.usf.edu","institution_ids":["https://openalex.org/I2613432"]},{"raw_affiliation_string":"Center for Evidence-based Medicine & Health Outcome Research, University of South Florida","institution_ids":["https://openalex.org/I2613432"]},{"raw_affiliation_string":"Department of Health Outcomes and Behavior, Moffitt Cancer Center & Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091393669","display_name":"Iztok Hozo","orcid":"https://orcid.org/0000-0003-2349-5707","observed_orcids":["https://orcid.org/0000-0003-2349-5707"]},"institutions":[{"id":"https://openalex.org/I4210093298","display_name":"Indiana University Northwest","ror":"https://ror.org/00n9fkm63","country_code":"US","type":"education","lineage":["https://openalex.org/I4210093298","https://openalex.org/I592451"]},{"id":"https://openalex.org/I592451","display_name":"Indiana University","ror":"https://ror.org/01kg8sb98","country_code":"US","type":"education","lineage":["https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Iztok Hozo","raw_affiliation_strings":["Department of Mathematics, Indiana University, Gary, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Mathematics, Indiana University, Gary, Indiana","institution_ids":["https://openalex.org/I4210093298","https://openalex.org/I592451"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084576368","display_name":"K. Wheatley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Keath Wheatley","raw_affiliation_strings":["University of Birmingham, Birmingham, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Birmingham, Birmingham, United Kingdom","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021167699","display_name":"Benjamin Djulbegovi\u0107","orcid":"https://orcid.org/0000-0003-0671-1447","observed_orcids":["https://orcid.org/0000-0003-0671-1447"]},"institutions":[{"id":"https://openalex.org/I2613432","display_name":"University of South Florida","ror":"https://ror.org/032db5x82","country_code":"US","type":"education","lineage":["https://openalex.org/I2613432"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin Djulbegovic","raw_affiliation_strings":["Center for Evidence-based Medicine & Health Outcome Research, University of South Florida","Department of Health Outcomes and Behavior, Moffitt Cancer Center & Research Institute, Tampa, Florida","Department of Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Evidence-based Medicine & Health Outcome Research, University of South Florida","institution_ids":["https://openalex.org/I2613432"]},{"raw_affiliation_string":"Department of Health Outcomes and Behavior, Moffitt Cancer Center & Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]},{"raw_affiliation_string":"Department of Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5100440708"],"corresponding_institution_ids":["https://openalex.org/I2613432","https://openalex.org/I3019308854"],"apc_list":{"value":5450,"currency":"USD","value_usd":5450},"apc_paid":null,"fwci":0.8537,"has_fulltext":true,"cited_by_count":42,"citation_normalized_percentile":{"value":0.60687593,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"86","issue":"1","first_page":"18","last_page":"24"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9539999961853027},{"id":"https://openalex.org/keywords/thalidomide","display_name":"thalidomide","score":0.953000009059906},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/melphalan","display_name":"melphalan","score":0.8880000114440918},{"id":"https://openalex.org/keywords/prednisone","display_name":"prednisone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9620000123977661},{"id":"https://openalex.org/keywords/event-free-survival","display_name":"event-free survival","score":0.9470000267028809},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7400000095367432},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.8399999737739563},{"id":"https://openalex.org/keywords/treatment-related-mortality","display_name":"non-relapse mortality","score":0.8410000205039978},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.890999972820282},{"id":"https://openalex.org/keywords/head-to-head-comparison","display_name":"head-to-head comparison","score":0.699999988079071},{"id":"https://openalex.org/keywords/indirect-comparison","display_name":"indirect comparison","score":0.6010000109672546},{"id":"https://openalex.org/keywords/previously-untreated-myeloma","display_name":"previously untreated myeloma","score":0.7170000076293945},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.6809999942779541},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.8489999771118164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8688384294509888},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.8436254262924194},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7025712728500366},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6995697617530823},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.646050751209259},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6107956171035767},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.6082859635353088},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5949797034263611},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5650259256362915},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.49849867820739746},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.47544193267822266},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.4292842745780945},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3808169662952423},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3718436360359192},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3328171968460083}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008558","descriptor_name":"Melphalan","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011241","descriptor_name":"Prednisone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/ajh.21904","doi":"https://doi.org/10.1002/ajh.21904","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.21904","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.21904","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},{"id":"pmid:21120867","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21120867","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of hematology","raw_type":"Journal Article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/4d62e29f-26a9-42cd-8881-5aa186058f54","doi":null,"is_oa":false,"landing_page_url":"https://research.birmingham.ac.uk/en/publications/4d62e29f-26a9-42cd-8881-5aa186058f54","pdf_url":null,"source":{"id":"https://openalex.org/S4306402634","display_name":"University of Birmingham Research Portal (University of Birmingham)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79619799","host_organization_name":"University of Birmingham","host_organization_lineage":["https://openalex.org/I79619799"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Kumar, A, Hozo, I, Wheatley, K & Djulbegovic, B 2007, 'Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: A systematic review', American Journal of Hematology, vol. 86, no. 1, pp. 18-24. https://doi.org/10.1002/ajh.21904","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1002/ajh.21904","doi":"https://doi.org/10.1002/ajh.21904","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.21904","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.21904","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2083480184.pdf","grobid_xml":"https://content.openalex.org/works/W2083480184.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W173435793","https://openalex.org/W186268426","https://openalex.org/W1964435302","https://openalex.org/W1989713968","https://openalex.org/W2005501262","https://openalex.org/W2005947177","https://openalex.org/W2009612604","https://openalex.org/W2010977839","https://openalex.org/W2028399237","https://openalex.org/W2033890227","https://openalex.org/W2082741854","https://openalex.org/W2084549330","https://openalex.org/W2085479354","https://openalex.org/W2099326967","https://openalex.org/W2101576302","https://openalex.org/W2103289287","https://openalex.org/W2107328434","https://openalex.org/W2110466835","https://openalex.org/W2125435699","https://openalex.org/W2126930838","https://openalex.org/W2133531206","https://openalex.org/W2140699272","https://openalex.org/W2143860449","https://openalex.org/W2147581820","https://openalex.org/W2157823046","https://openalex.org/W2550787877","https://openalex.org/W2752308580","https://openalex.org/W4229668175"],"related_works":["https://openalex.org/W2565641385","https://openalex.org/W2587560657","https://openalex.org/W2293290359","https://openalex.org/W2319561761","https://openalex.org/W2169822818","https://openalex.org/W2119924751","https://openalex.org/W2059857442","https://openalex.org/W2598505750","https://openalex.org/W3029944047","https://openalex.org/W2725388504"],"abstract_inverted_index":{"Thalidomide":[0,38],"(T)":[1],"or":[2],"bortezomib":[3],"(B)":[4],"in":[5,131,181],"combination":[6],"with":[7,189],"melphalan":[8],"plus":[9,31,37],"prednisone":[10],"(MP)":[11],"is":[12,40,233,255],"superior":[13],"to":[14,47],"MP":[15,59,110,156],"as":[16,81],"first":[17],"line":[18],"therapy":[19],"for":[20,164,205,212],"previously":[21],"untreated":[22],"myeloma.":[23],"However,":[24],"direct":[25,248],"head-to-head":[26,249],"comparison":[27,193,250],"of":[28,52,92,107,153,194,239,242],"Melphalan,":[29,35],"Prednisone":[30,36],"Bortezomib":[32],"(MPB)":[33],"versus":[34,54,109,196,203],"(MPT)":[39],"lacking.":[41],"We":[42],"performed":[43,80],"an":[44,234],"indirect":[45,192],"meta-analysis":[46],"assess":[48],"the":[49,61,83,103,245],"treatment":[50],"effects":[51],"MPB":[53,154,195,202],"MPT":[55,108,135,197,204],"via":[56],"common":[57],"comparator":[58],"using":[60],"systematic":[62],"review":[63,78],"and":[64,72,171,220],"meta-analytical":[65],"techniques.":[66],"A":[67],"comprehensive":[68],"literature":[69],"search":[70,88],"(MEDLINE":[71],"gray":[73],"literature)":[74],"was":[75,79],"undertaken.":[76],"Systematic":[77],"per":[82],"Cochrane":[84],"Collaboration":[85],"recommendations.":[86],"Initial":[87],"yielded":[89],"1,013":[90],"citations,":[91],"which":[93],"six":[94],"randomized":[95],"controlled":[96],"trials":[97],"(RCTs)":[98],"enrolling":[99],"2,798":[100],"patients":[101],"met":[102],"inclusion":[104],"criteria.":[105],"Comparison":[106,152],"(five":[111],"RCTs)":[112],"showed":[113,159,198],"no":[114,199],"survival":[115,133,165,173],"difference":[116,130,180,200],"[hazard":[117],"ratio":[118,146],"(HR)":[119],"0.82,":[120],"95%":[121,138,149,168,176,186,217,227],"confidence":[122],"interval":[123],"(CI)":[124],"0.64-1.05]":[125],"but":[126,208],"a":[127,160,209],"statistically":[128,161],"significant":[129,162,210],"event-free":[132,172],"favoring":[134,230],"(HR":[136,166,174],"0.66,":[137],"CI":[139,150,169,177,187,218,228],"0.56-0.77)":[140],"without":[141,179],"excessive":[142],"treatment-related":[143,182],"mortality":[144,183],"[risk":[145],"(RR)":[147],"1.11,":[148],"0.64-1.92].":[151],"vs.":[155],"(one":[157],"RCT)":[158],"benefit":[163,211],"0.65,":[167],"0.51-0.84)":[170],"0.48,":[175],"0.37-0.63)":[178],"(RR":[184,215,225],"0.42,":[185],"0.11-1.63)":[188],"MPB.":[190,231],"The":[191],"between":[201,251],"all":[206],"outcomes":[207],"complete":[213],"response":[214],"2.34,":[216],"1.12-4.90),":[219],"grade":[221],"III/IV":[222],"adverse":[223],"events":[224],"0.53,":[226],"0.38-0.73)":[229],"There":[232],"uncertainty":[235],"about":[236],"definitive":[237],"superiority":[238],"one":[240],"type":[241],"regimen":[243],"over":[244],"other.":[246],"Therefore,":[247],"these":[252],"competing":[253],"regimens":[254],"warranted.":[256]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}